Assessing cost-effectiveness of drug interventions for schizophrenia

References

• American Psychiatric Association. Practice Guidelines for the Treatment of Schizophrenia. American Psychiatric Press, Washington DC 1996
   Google Scholar
• Access Economics. Schizophrenia: costs an analysis of the burden of schizophrenia and related suicide in Australia. SANE Australia, Melbourne 2002
   Google Scholar
• Awad A G, Voruganti L NP. Quality of life and new antipsychotics in schizophrenia. Are patients better off?. International Journal of Social Psychiatry 1999; 45: 268–275
   PubMed Web of Science ®Google Scholar
• McGorry P, Killackey E, Lambert M, Lambert T. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). Australasian Psychiatry 2003; 11: 136–147
   Google Scholar
• National Institute for Clinical Excellence. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. National Collaborating Centre for Mental Health, London 2002
   Google Scholar
• Haby M, Carter R, Mihalopoulos C, et al. Assessing cost-effectiveness – Mental health. Introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004; 38: 569–578
   PubMed Web of Science ®Google Scholar
• Jablensky A, McGrath J, Herrman H, et al. People living with psychotic illness: an Australian study 1997–98. Department of Health and Aged Care, Canberra 1999
   Google Scholar
• Lewin T J, Carr V J. Rates of treatment of schizophrenia general practitioners. A pilot study. Medical Journal of Australia 1998; 168: 166–169
   PubMedGoogle Scholar
• Harding C M, Brooks G W, Ashigawa T, Strauss J S, Breier A. The Vermont Longitudinal Sudy of persons with severe mental illness, 1: Methodology, study sample, and overall status 32 years later. American Journal of Psychiatry 1987; 144: 718–726
   PubMed Web of Science ®Google Scholar
• Ciompi L. Three lectures in schizophrenia. The natural history of schizophrenia in the long term. British Journal of Psychiatry 1980; 136: 413–420
   PubMed Web of Science ®Google Scholar
• Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?. Acta Psychiatrica Scandinavica 1990; 81: 231–235
   PubMed Web of Science ®Google Scholar
• Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J. Recovery from psychotic illness: a 15- and 25-year international follow-up study. British Journal of Psychiatry 2001; 178: 506–517
   PubMed Web of Science ®Google Scholar
• Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies schizophrenic patients. Schizophrenia Bulletin 1980; 6: 592–605
   PubMed Web of Science ®Google Scholar
• Gaebel W. Towards the improvement of compliance: significance of psycho-education and new antipsychotic drugs. International Clinical Psychopharmacology 1997; 12: S37–S42
   PubMedGoogle Scholar
• Marder S R. Facilitating compliance with antipsychotic medication. Journal of Clinical Pharmacology 1998; 58: 21–25
   Google Scholar
• Harris E, Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998; 173: 11–53
   PubMed Web of Science ®Google Scholar
• Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A. The Australian national survey of psychotic disorders: profile of psychosocial disability and its risk factors. Psychological Medicine 2002; 32: 639–647
   PubMed Web of Science ®Google Scholar
• Stouthard M, Essink-Bot M, Bonsel G, et al. Disability Weights for Diseases in the Netherlands. Department of Public Health Erasmus University, Rotterdam 1997
   Google Scholar
• Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford 2003
   Google Scholar
• Duggan L, Fenton M, Dardennes R M, El-Dosoky A, Indran S. Olanzapine for schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford 2003
   Google Scholar
• Gilbody S M, Bagnall A M, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford 2003
   Google Scholar
• Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford 2003
   Google Scholar
• Wahlbeck K, Cheine M, Essali M. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford 2003
   Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal of 2000; 321: 1371–1376
   PubMed Web of Science ®Google Scholar
• Waraich P, Adams C E, Roque M, Hamill K, Marti J. Haloperidol dose for the acute phase of schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford 2003
   Google Scholar
• Csernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medicine 2002; 346: 16–22
   PubMed Web of Science ®Google Scholar
• Egger M, Smith G, Altman D. Systematic reviews in health care: meta-analysis in context 2nd edn. BMJ, London 2001
   Google Scholar
• Willett W, Manson J, Stampfer M, et al. Weight, weight change and coronary heart disease in women: risk within the ‘normal’ weight range. Journal of the American Medical Society 1995; 273: 461–465
   PubMed Web of Science ®Google Scholar
• Rexrode K, Hennekens C, Willett W, et al. A prospective study of body mass index, weight change and risk of stroke in women. Journal of American Medical Association 1997; 275: 447–451
   Google Scholar
• Lee I, Paffenbarger R J. Quetelet's index and risk of colon cancer in college alumni. Journal of the National Cancer Institute 1992; 84: 1326–1331
   PubMedGoogle Scholar
• Colditz G, Willett W, Rotnitsky A, Manson J. Weight gain risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine 1995; 122: 481–486
   PubMed Web of Science ®Google Scholar
• Department of Human Services. Victorian Burden of Disease Study: morbidity. Department of Human Services, Melbourne 1999
   Google Scholar
• Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. British Journal of Psychiatry 2003; 182: 505–508
   PubMed Web of Science ®Google Scholar
• Hamilton S H, Edgell E T, Revicki D A, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European subsample. International Clinical Psychopharmacology 2000; 15: 245–255
   PubMed Web of Science ®Google Scholar
• Tran P V, Hamilton S H, Kuntz A J, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997; 17: 407–418
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997; 337: 809–815
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 2000; 43: 135–145
   PubMed Web of Science ®Google Scholar
• Hellewell J. Patients' subjective experiences of antipsychotics. Clinical relevance. CNS Drugs 2002; 16: 457–471
   PubMed Web of Science ®Google Scholar
• Emsley R A. Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophrenia Bulletin 1999; 25: 721–729
   PubMed Web of Science ®Google Scholar
• Coulter D M, Bate A, Meyboom R HB, Lindquist M, Edwards I R. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. British Medical Journal 2001; 322: 1207–1209
   PubMed Web of Science ®Google Scholar
• Kilian J G, Kerr K, Lawrence C, Celermajer D S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–1845
   PubMed Web of Science ®Google Scholar
• Owen R R, Fischer E P, Booth B M, Cuffel B J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services 1996; 47: 853–858
   PubMed Web of Science ®Google Scholar
• Gureje O, Herrman H, Harvey C, Trauer T, Jablensky A. Defining disability in psychosis: Performance of the diagnostic interview for psychosis-disability module (DIP-DIS) in the Australian national survey of psychotic disorders. Australian and New Zealand Journal of Psychiatry 2001; 35: 846–851
   PubMed Web of Science ®Google Scholar
• Davis J, Chen N, Glick I. A Meta-analysis of the efficacy second-generation antipsychotics. Archives of General Psychiatry 2003; 60: 553–564
   PubMed Web of Science ®Google Scholar
• Almond S, O'Donnell O. Cost analysis of the treatment schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383–389
   PubMed Web of Science ®Google Scholar
• Palmer C S, Revicki D A, Genduso L A, Hamilton S H, Brown R E. A cost-effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 1998; 4: 345–355
   PubMed Web of Science ®Google Scholar
• Glazer W M, Johnstone B M. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 1997; 58: 50–54
   PubMedGoogle Scholar
• Albright P, Livingstone S, Keegan D L, Ingham M, Shrikhande S, Le Lorier J. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clinical Pharmacoeconomics 1996; 11: 289–299
   Google Scholar
• Geddes J. Generating evidence to inform policy and The example of the second generation ‘atypical’ antipsychotics. Schizophrenia Bulletine 2003; 29: 105–114
   PubMedGoogle Scholar
• Carr V J, Neil A L, Halpin S A, Holmes S, Lewin T J. Costs schizophrenia and other psychoses in urban Australia: findings from the low prevalence (psychotic) disorders study. Australian and New Zealand Journal of Psychiatry 2003; 37: 31–40
   PubMed Web of Science ®Google Scholar
• Davies A, Adena M A, Keks N A, Catts S V, Lambert T, Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clinical Therapeutics 1998; 20: 58–71
   PubMed Web of Science ®Google Scholar
• Jablensky A. Epidemiology of schizophrenia. Australasian Epidemiologist 2002; 9: 2–8
   Google Scholar
• Sanderson K, Andrews G, Corry J, Lapsley H. Using the size to model change in preference values from descriptive health states. Quality of Life Research 2004; 13: 1255–1264
   PubMed Web of Science ®Google Scholar
• Carr V J, Neil A L, Halpin S A, Holmes S. Costs of psychosis in urban Australia. A bulletin of the low prevalence disorders study. Centre for Mental Health Studies and the Universtity of Newcastle, Newcastle 2000
   Google Scholar
• Britt H, Miller G, Knox C, et al. General practice activity in Australia 2000–01. (General Practice Series no. 8.), Australian Institute of Health and Welfare, Canberra 2001, AIHW Cat. No. GEP8
   Google Scholar
• Davies A, Langley P C, Keks N A, Catts S V, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clinical Therapeutics 1998; 20: 196–212
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised control trials. Schizophrenia Research 1999; 35: 51–68
   PubMed Web of Science ®Google Scholar
• Allison D B, Mentore J L, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Beasley C M, Tollefson G D, Tran P V, Satterlee W, Sanger T, Hamilton S H. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–123
   PubMed Web of Science ®Google Scholar
• Mauskopf J A, Muroff M, Gibson P J, Grainger D L. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophrenia Bulletin of the 2002; 28: 619–635
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatmnent of refractory schizophrenia. Health Services Research 1998; 33: 1237–1267
   PubMed Web of Science ®Google Scholar
• Zhao Z. A retrospective evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Managed Care Interface 2002; 15: 75–81
   PubMedGoogle Scholar